TAO SYNERGIES INC
TAOXNASDAQ🏆 #4549 by market capUS Equity
$3.21▲ $0.05 (+1.74%)
Pre-market · at closeTrack TAOX
Get earnings, price moves & breaking news on Telegram
24h▲ 1.7%
7d▼ 5.0%
14d▼ 10.6%
30d▼ 25.3%
ytd▼ 13.7%
1y▼ 59.1%
🏦Market Cap
$24M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
33.1x
Expensive
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $3.09 – $3.21
- 52-Week Range
- $3.07 – $9.43
- Volume (shares)
- 1,114
- Avg Volume (shares)
- —
- Shares Outstanding
- 7.5M
- Next Earnings
- —
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- 33.1x
- EPS (TTM)
- $-3.38
- Dividend Yield
- 2.46%
TAO SYNERGIES INC
TAOXFinancial Trends
Financial history unavailable.
StockOtter · stockotter.spaceAbout TAO SYNERGIES INC
TAO Synergies Inc. operates as a biopharmaceutical company currently in the clinical development stage. It is dedicated to advancing a bryostatin-1 therapeutic platform, specifically designed to combat Alzheimer's and various other neurodegenerative and cognitive disorders. Beyond its drug development efforts, the firm is also diversifying its treasury strategy, with a new approach centered on the management of digital assets, primarily focusing on the acquisition and 'staking' of TAO cryptocurrency.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
⚖️Valuation★★★★★
Overall Score
Insufficient data
—/100
Analyst Ratings
ⓘConsensus
Buy
7 analysts
Strong Buy2
Buy4
Hold1
Sell0
Strong Sell0
Ratings as of Apr 2025
Latest News & Updates
News unavailable.